Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies

Yanhong Li, Hongzhi Cao, Hai Yu, Yi Chen, Kam Lau, Jingyao Qu, Vireak Thon, Go Sugiarto, Xi Chen

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Aberrant expression of human sialidases has been shown to associate with various pathological conditions. Despite the effort in the sialidase inhibitor design, less attention has been paid to designing specific inhibitors against human sialidases and characterizing the substrate specificity of different sialidases regarding diverse terminal sialic acid forms and sialyl linkages. This is mainly due to the lack of sialoside probes and efficient screening methods, as well as limited access to human sialidases. A low cellular expression level of the human sialidase NEU2 hampers its functional and inhibitory studies. Here we report the successful cloning and expression of the human sialidase NEU2 in E. coli. About 11 mg of soluble active NEU2 was routinely obtained from 1 L of E. coli cell culture. Substrate specificity studies of the recombinant human NEU2 using twenty p-nitrophenol (pNP)-tagged α2-3- or α2-6-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid (Neu5Ac), non-human N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-d-glycero-d- galacto-nonulosonic acid (Kdn), or their C5-derivatives in a microtiter plate-based high-throughput colorimetric assay identified a unique structural feature specifically recognized by the human NEU2 but not two bacterial sialidases. The results obtained from substrate specificity studies were used to guide the design of a sialidase inhibitor that was selective against human NEU2. The selectivity of the inhibitor was revealed by the comparison of sialidase crystal structures and inhibitor docking studies.

Original languageEnglish (US)
Pages (from-to)1060-1072
Number of pages13
JournalMolecular BioSystems
Volume7
Issue number4
DOIs
StatePublished - Apr 1 2011

Fingerprint

Substrate Specificity
Neuraminidase
N-Acetylneuraminic Acid
Escherichia coli
Galactosides
human NEU2 protein
Organism Cloning
Cell Culture Techniques
Acids

ASJC Scopus subject areas

  • Biotechnology
  • Molecular Biology

Cite this

Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies. / Li, Yanhong; Cao, Hongzhi; Yu, Hai; Chen, Yi; Lau, Kam; Qu, Jingyao; Thon, Vireak; Sugiarto, Go; Chen, Xi.

In: Molecular BioSystems, Vol. 7, No. 4, 01.04.2011, p. 1060-1072.

Research output: Contribution to journalArticle

Li, Yanhong ; Cao, Hongzhi ; Yu, Hai ; Chen, Yi ; Lau, Kam ; Qu, Jingyao ; Thon, Vireak ; Sugiarto, Go ; Chen, Xi. / Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies. In: Molecular BioSystems. 2011 ; Vol. 7, No. 4. pp. 1060-1072.
@article{ed063498bdda4a33ad9a4535fe809cc6,
title = "Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies",
abstract = "Aberrant expression of human sialidases has been shown to associate with various pathological conditions. Despite the effort in the sialidase inhibitor design, less attention has been paid to designing specific inhibitors against human sialidases and characterizing the substrate specificity of different sialidases regarding diverse terminal sialic acid forms and sialyl linkages. This is mainly due to the lack of sialoside probes and efficient screening methods, as well as limited access to human sialidases. A low cellular expression level of the human sialidase NEU2 hampers its functional and inhibitory studies. Here we report the successful cloning and expression of the human sialidase NEU2 in E. coli. About 11 mg of soluble active NEU2 was routinely obtained from 1 L of E. coli cell culture. Substrate specificity studies of the recombinant human NEU2 using twenty p-nitrophenol (pNP)-tagged α2-3- or α2-6-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid (Neu5Ac), non-human N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-d-glycero-d- galacto-nonulosonic acid (Kdn), or their C5-derivatives in a microtiter plate-based high-throughput colorimetric assay identified a unique structural feature specifically recognized by the human NEU2 but not two bacterial sialidases. The results obtained from substrate specificity studies were used to guide the design of a sialidase inhibitor that was selective against human NEU2. The selectivity of the inhibitor was revealed by the comparison of sialidase crystal structures and inhibitor docking studies.",
author = "Yanhong Li and Hongzhi Cao and Hai Yu and Yi Chen and Kam Lau and Jingyao Qu and Vireak Thon and Go Sugiarto and Xi Chen",
year = "2011",
month = "4",
day = "1",
doi = "10.1039/c0mb00244e",
language = "English (US)",
volume = "7",
pages = "1060--1072",
journal = "Molecular BioSystems",
issn = "1742-206X",
publisher = "Royal Society of Chemistry",
number = "4",

}

TY - JOUR

T1 - Identifying selective inhibitors against the human cytosolic sialidase NEU2 by substrate specificity studies

AU - Li, Yanhong

AU - Cao, Hongzhi

AU - Yu, Hai

AU - Chen, Yi

AU - Lau, Kam

AU - Qu, Jingyao

AU - Thon, Vireak

AU - Sugiarto, Go

AU - Chen, Xi

PY - 2011/4/1

Y1 - 2011/4/1

N2 - Aberrant expression of human sialidases has been shown to associate with various pathological conditions. Despite the effort in the sialidase inhibitor design, less attention has been paid to designing specific inhibitors against human sialidases and characterizing the substrate specificity of different sialidases regarding diverse terminal sialic acid forms and sialyl linkages. This is mainly due to the lack of sialoside probes and efficient screening methods, as well as limited access to human sialidases. A low cellular expression level of the human sialidase NEU2 hampers its functional and inhibitory studies. Here we report the successful cloning and expression of the human sialidase NEU2 in E. coli. About 11 mg of soluble active NEU2 was routinely obtained from 1 L of E. coli cell culture. Substrate specificity studies of the recombinant human NEU2 using twenty p-nitrophenol (pNP)-tagged α2-3- or α2-6-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid (Neu5Ac), non-human N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-d-glycero-d- galacto-nonulosonic acid (Kdn), or their C5-derivatives in a microtiter plate-based high-throughput colorimetric assay identified a unique structural feature specifically recognized by the human NEU2 but not two bacterial sialidases. The results obtained from substrate specificity studies were used to guide the design of a sialidase inhibitor that was selective against human NEU2. The selectivity of the inhibitor was revealed by the comparison of sialidase crystal structures and inhibitor docking studies.

AB - Aberrant expression of human sialidases has been shown to associate with various pathological conditions. Despite the effort in the sialidase inhibitor design, less attention has been paid to designing specific inhibitors against human sialidases and characterizing the substrate specificity of different sialidases regarding diverse terminal sialic acid forms and sialyl linkages. This is mainly due to the lack of sialoside probes and efficient screening methods, as well as limited access to human sialidases. A low cellular expression level of the human sialidase NEU2 hampers its functional and inhibitory studies. Here we report the successful cloning and expression of the human sialidase NEU2 in E. coli. About 11 mg of soluble active NEU2 was routinely obtained from 1 L of E. coli cell culture. Substrate specificity studies of the recombinant human NEU2 using twenty p-nitrophenol (pNP)-tagged α2-3- or α2-6-linked sialyl galactosides containing different terminal sialic acid forms including common N-acetylneuraminic acid (Neu5Ac), non-human N-glycolylneuraminic acid (Neu5Gc), 2-keto-3-deoxy-d-glycero-d- galacto-nonulosonic acid (Kdn), or their C5-derivatives in a microtiter plate-based high-throughput colorimetric assay identified a unique structural feature specifically recognized by the human NEU2 but not two bacterial sialidases. The results obtained from substrate specificity studies were used to guide the design of a sialidase inhibitor that was selective against human NEU2. The selectivity of the inhibitor was revealed by the comparison of sialidase crystal structures and inhibitor docking studies.

UR - http://www.scopus.com/inward/record.url?scp=79952689648&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952689648&partnerID=8YFLogxK

U2 - 10.1039/c0mb00244e

DO - 10.1039/c0mb00244e

M3 - Article

VL - 7

SP - 1060

EP - 1072

JO - Molecular BioSystems

JF - Molecular BioSystems

SN - 1742-206X

IS - 4

ER -